CAMBRIDGE, Mass., May 21 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) announced today that Nicolas Barthelemy has been
appointed Vice President, Manufacturing and General Manager of the Company's
Research Triangle Park (RTP), North Carolina facility. Mr. Barthelemy will
supervise Biogen's RTP operations, which is now home to the large-scale
manufacturing plant (LSM), one of the largest cell culture facilities in the
world, and more than 300 employees. He will also oversee the Cambridge
manufacturing site and its 150 employees. He reports to Sylvie Gregoire,
Pharm.D., Executive Vice President, Technical Operations.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Dr. Gregoire said, "Nicolas has played a critical role in making RTP a
world-class manufacturing facility. The addition of the LSM gives Biogen one
of the largest biologic manufacturing capacities in the world, and the
flexibility to produce multiple products in our growing pipeline. Nicolas'
leadership as general manager and diverse experience will be critical for
Biogen to maintain a first-rate manufacturing capability and for RTP to become
a multifunctional operation."
Mr. Barthelemy was most recently Director of Manufacturing in RTP, where
he oversaw 140 people in the manufacturing, validation, materials management
and technical services groups during a period of rapid growth and the start-up
of the LSM. He joined Biogen in 1996 as Manager, European Supply Chain. From
1998 to 2000 he was Regional Manager, Distributors and then Associate
Director, International Distributors, supervising the sales, marketing and
product launch responsibilities of AVONEX(R) (Interferon beta-1a) in over 30
international markets. Mr. Barthelemy subsequently served as a member of the
senior management team responsible for establishing Biogen's presence in Asia.
Prior to joining Biogen, he was at Merck & Co., Inc., where he worked in
Technical Operations.
Mr. Barthelemy received a Master of Science in Physics and Chemistry from
Ecole Superieure de Physiques et Chimie Industrielles in Paris, France. He
also received a Master of Science in Chemical Engineering at University of
California at Berkeley and attended the Harvard Business School Program for
Management Development.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, (Please see full prescribing information at
http://www.avonex.com.), and from the worldwide sales by licensees of a number
of products, including alpha interferon and hepatitis B vaccines and
diagnostic products. Biogen's research and development activities are focused
on novel products to treat inflammatory and autoimmune diseases, neurological
diseases, cancer, fibrosis and congestive heart failure. The Company
maintains active clinical research programs in protein therapeutics, small
molecules, genomics and gene therapy. For copies of press releases and
additional information about the Company, please consult Biogen's homepage on
the World Wide Web at http://www.biogen.com.
Media Contact:
Amy Brockelman
Manager, Public Affairs
Biogen, Inc.
Tel: (617) 679-3860
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2521
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Amy Brockelman, Manager, Public Affairs,
+1-617-679-3860, or Christina Dillon, Manager, Investor
Relations, +1-617-679-2521, both of Biogen, Inc.
|
